FIVE-FOR-CO.,-LTD.
6.3.2019 06:00:18 CET | Business Wire | Press release
Five for Co., Ltd. (Location: Chiyoda-ku Ward, Tokyo, Representative Director: Takayoshi Tanigawa) will open a VR experience entertainment facility, “VR NINJA DOJO” which provides Ninja experience for foreigners visiting Japan on Monday, March 18th, 2019 in Uchikanda, Chiyoda-ku, Tokyo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190305006076/en/
VR NINJA DOJO is an entertainment facility that provides “Ninja Experience” fusing the real and virtual world for foreigners visiting Japan. One of Japanese cultures, “Ninja”, is also literally popular as “Ninja” overseas. The facility is designed with the stylistic beauty inherent in Japan and is a space where you can feel the unique perspective of the Japan world. Also, this facility is designed with our own technology so that the third parties who do not wear a head-mount display can enjoy the virtual world as well. So, you can unite and enjoy the experience even when your group consists of two or more people. Furthermore, since we explain the operation completely in English, foreigners visiting Japan comfortably use the facility. Visitors will take the full proficiency examination to be a Ninja master through the VR experience after they had realistic discipline and training by doing physical activities.
Recently, the number of foreign visitors has been on the rise in Japan. According to Japan National Tourism Organization (JNTO), the total number of foreign visitors to Japan in 2018 exceeded 30,010,000, which is the first time ever recorded over 30 million people and is an increase of 8.7% from the previous year. It is expected that the number of foreign visitors to Japan will further increase by 2020, but there is some change in their consumption behavior. In the past, "entity-oriented consumption" such as purchasing large quantities of home appliances and cosmetics etc. was mainstream. But, as the EC industry has expanded, there is less value in traveling some places in order to purchase goods there. Instead, "situation-oriented consumption" such as taking experience type services including hot spring tours and kimono experiences is on the increase. The new facility in anticipation of the growing inbound demand provides a new entertainment that will definitely become popular among foreign visitors to Japan.
VR NINJA DOJO provides a Ninja experience, which is only available here, with the concept of “The Hospitality of Japanese Culture in both the 'real' and the 'virtual' world."
|
[Contents of the Experience] |
| The required time for a Ninja Experience is from 75 minutes to 90 minutes, and up to 10 persons in one group can participate. |
| Ninja cosplay experience |
| - Ninja discipline and training in the real and the virtual world |
| - Full proficiency examination (VR experience) |
| - VR ceremonial photograph |
| - Presentation of handscroll type certificate |
|
[Details of the Facility] |
||
|
The Name of the Facility: |
VR NINJA DOJO |
|
|
Opening Date: |
March 18th, 2019 |
|
|
Location of the Facility: |
Takebashi Bldg. 1F, 2-15-15 Uchikanda, Chiyoda-ku, |
|
| Tokyo 101-0047 | ||
|
Eligible Person for the Experience: Foreign residents and tourists in Japan |
||
|
- One accompanying Japanese person per a foreigner is free of charge. |
||
| (Ninja costume and the handscroll type certificate are not included.) | ||
|
- There is a special plan available catering to Japanese only. |
||
|
Official Site: |
||
|
[Company Profile] |
||
|
Company Name: |
Five for Co., Ltd. |
|
|
Date of Establishment: |
March 14th, 2017 |
|
|
Representative Director: |
Takayoshi Tanigawa |
|
|
Location: |
Uchikanda Chuo Bldg. 7F, 1-18-13 Uchikanda, |
|
| Chiyoda-ku, Tokyo 101-0047 | ||
|
Business Description: |
VR Entertainment Content Produce & Development |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305006076/en/
Contact:
VR NINJA DOJO PR SBY Co., Ltd. Inada / Arai (Antil Co., Ltd. Akazaki Ichika / Sato Katsuhiko / Yoshida Yusei) TEL: (+81) 3-5572-6061 FAX: (+81) 3-6685-5267 E-mail: vr_ninjadojo@vectorinc.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom